-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBX-1325 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UBX-1325 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UBX-1325 in Diabetic Macular Edema Drug Details: UBX-1325 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: JTE-451...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GI-301 in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-301 in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Allergic Asthma Drug Details: GI-301 is under development for chronic...
-
Thematic Analysis
Construction M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Construction Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GI-301 in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-301 in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Chronic Urticaria Or Hives Drug Details: GI-301 is...
-
Company Insights
Innovation and Patenting activity of General Interface Solution (GIS) Holding Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of General Interface Solution (GIS) Holding Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Colon Cancer Drug Details: Nadunolimab (CAN-04) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lisaftoclax in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisaftoclax in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisaftoclax in Multiple Myeloma (Kahler Disease) Drug Details: Lisaftoclax (APG...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...